Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Testicular cancer.

R T Oliver1

  • 1Department of Medical Oncology, St Barts & Royal London School of Medicine, London, UK. e.m.davies@mds.qmw.ac.uk

Current Opinion in Oncology
|April 18, 2001
PubMed
Summary
This summary is machine-generated.

Testis cancer survival rates vary globally, but advancements like high-dose chemotherapy offer hope. Research explores genetic links and environmental factors, emphasizing safe treatment minimization for better outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Single-agent carboplatin AUC10 for metastatic seminoma with IGCCCG good prognosis disease; a feasibility study of the Orchid Clinical Trials Group.

Annals of oncology : official journal of the European Society for Medical Oncology·2010
Same author

Aphorisms in cancer surgery.

Annals of the Royal College of Surgeons of England·2009
Same author

Prognostic factors for renal cell carcinoma.

Cancer treatment reviews·2008
Same author

Introduction: Clonal evolution in bladder cancer: a scientific and clinical perspective.

Cancer surveys·2004
Same author

Squamous change in bladder cancer and its relevance to understanding clonal evolution in development of bladder cancer.

Cancer surveys·2004
Same author

Malignancy associated papillomaviruses and morphology of human bladder cancer.

Cancer surveys·2004
Same journal

Artificial intelligence-augmented robotic surgery in gynecologic oncology: intraoperative assistance and analytics.

Current opinion in oncology·2026
Same journal

Artificial intelligence in cervical cancer screening and triage: a role-stratified systematic review and bivariate meta-analysis.

Current opinion in oncology·2026
Same journal

Deep learning assisting the surgical management of gynecologic cancers.

Current opinion in oncology·2026
Same journal

Pain management in pancreatic cancer: time to change our strategy!

Current opinion in oncology·2026
Same journal

Systemic radionuclide treatments in gastro-entero-pancreatic neuroendocrine tumours.

Current opinion in oncology·2026
Same journal

5-Fluorouracil at seventy: still attractive but barely understood. A cautionary tale for drug development.

Current opinion in oncology·2026
See all related articles

Area of Science:

  • Oncology
  • Genetics
  • Environmental Health

Background:

  • Testis cancer survival rates show significant global disparities, with Kenya reporting 39% 5-year survival versus 62% after advanced chemotherapy for metastatic nonseminoma.
  • The success of cancer survivors, like Lance Armstrong, highlights the potential for complete cures and underscores the need for public education and scientific inquiry into the unique biology of testis cancer.
  • Environmental factors, particularly damage to fertility, are increasingly recognized as significant risk factors for testis cancer development.

Purpose of the Study:

  • To highlight the significant global disparities in testis cancer survival rates.
  • To emphasize the importance of understanding the scientific basis for testis cancer's unique curability.
  • To discuss ongoing debates in the early management and adjuvant treatment of testis cancer, and the long-term effects of chemotherapy.

Related Experiment Videos

Main Methods:

  • Review of survival data and treatment outcomes for testis cancer.
  • Analysis of scientific breakthroughs, including genetic susceptibility.
  • Examination of clinical controversies in disease management and late treatment-related events.

Main Results:

  • High-dose chemotherapy demonstrates significant efficacy in metastatic nonseminoma.
  • Genetic research has identified a specific region on the X chromosome linked to testis cancer susceptibility and undescended testis.
  • Concerns exist regarding late adverse events from chemotherapy, such as leukemia and cardiovascular issues, potentially linked to cisplatin dosage.

Conclusions:

  • Minimizing treatment while maintaining high cure rates is a key objective in testis cancer management.
  • Further research is needed to understand the environmental impact on germ cell health and testis cancer risk.
  • Continued investigation into the genetic and environmental underpinnings of testis cancer is crucial for improving global outcomes.